IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc., (NasdaqGM: SPPI) today announced the selection of FUSILEV™ (levoleucovorin) for injection as the trade name for levoleucovorin, the company’s proprietary drug which was approved by the FDA on March 7, 2008. FUSILEV™ is indicated after high-dose methotrexate therapy in patients with osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists. As a result, the Company anticipates FUSILEV™ being available to doctors and patients in mid-August 2008.
